Chemplast Sanmar (CHEMPLASTS) Q4 25/26 earnings summary

Executive summary

• FY 2025-26 was challenging, with consolidated revenue at ₹4,224 crore and EBITDA at ₹198 crore, both declining year-over-year due to price pressures, global overcapacity, and regulatory disruptions.

• Audited standalone and consolidated financial results for the year ended 31 March 2026 were approved, with auditors issuing an unmodified opinion.

• The company recorded a significant impairment loss of ₹898 crore and exceptional charges due to adverse market conditions and regulatory changes.

• A committee of independent directors was formed to evaluate strategic priorities, including potential reorganization and M&A.

• No dividend was recommended for FY 2025-26.

Financial highlights

• Q4 FY 2026 consolidated revenue was ₹1,256 crore, up 9% year-on-year; EBITDA at ₹194 crore, up 424% year-on-year.

• FY 2026 consolidated revenue was ₹4,224 crore, down 3% year-over-year; EBITDA was ₹198 crore, down 9%; net loss for the year was ₹280 crore.

• Standalone FY 2026 net loss was ₹1,003 crore after impairment provision.

• Consolidated net debt as of March 31, 2026 stood at ₹1,419 crore, up from ₹1,117 crore in FY '25.

• Net cash from operations increased to ₹294 crore in FY '26 from ₹172 crore in FY '25.

Outlook and guidance

• Commodity business expected to face continued volatility due to geopolitical and supply chain uncertainties.

• Speciality business projected to perform strongly, supported by robust fundamentals and expansion projects.

• Focus remains on operational efficiency, cost optimization, and capacity utilization.

• Custom Manufactured Chemicals segment expects recovery with a strong order book for FY 2027.

• Committee of independent directors will evaluate strategic options to enhance long-term value, including potential reorganizations and M&A.